3B Blackbio DX Ltd

3B Blackbio Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

3B Blackbio DX Ltd

₹ 1,153 -0.37%
03 Jul 10:41 a.m.
kilpest.com BSE: 532067
About

Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]

Key Points

Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit

Website BSE
  • Market Cap ₹ 990 Cr.
  • Current Price ₹ 1,153
  • High / Low ₹ 1,262 / 410
  • Stock P/E 29.0
  • Book Value ₹ 265
  • Dividend Yield 0.22 %
  • ROCE 36.6 %
  • ROE 27.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 140% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 25.6%
  • Promoter holding has increased by 2.86% over last quarter.

Cons

  • Earnings include an other income of Rs.12.3 Cr.
  • Company has high debtors of 188 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
3.87 3.52 4.41 2.39 5.21 2.31 17.37 13.64 17.77 13.21 18.57 16.96 21.99
4.73 3.53 4.46 2.65 5.99 2.29 7.94 6.42 9.61 6.52 9.91 7.37 11.84
Operating Profit -0.86 -0.01 -0.05 -0.26 -0.78 0.02 9.43 7.22 8.16 6.69 8.66 9.59 10.15
OPM % -22.22% -0.28% -1.13% -10.88% -14.97% 0.87% 54.29% 52.93% 45.92% 50.64% 46.63% 56.54% 46.16%
0.67 1.02 8.06 0.42 0.59 0.40 2.05 2.88 1.19 2.96 2.75 2.47 4.15
Interest 0.04 0.03 0.06 0.03 -0.02 0.03 0.07 0.05 0.05 0.02 0.04 0.02 0.04
Depreciation 0.04 0.05 0.05 0.10 0.09 0.07 0.17 0.19 0.28 0.18 0.22 0.20 0.27
Profit before tax -0.27 0.93 7.90 0.03 -0.26 0.32 11.24 9.86 9.02 9.45 11.15 11.84 13.99
Tax % 11.11% 15.05% 3.42% -300.00% -50.00% 25.00% 23.13% 22.11% 35.92% 20.95% 23.95% 22.30% 35.31%
-0.23 0.78 7.63 0.12 -0.39 0.24 8.65 7.68 5.78 7.47 8.48 9.21 9.06
EPS in Rs -0.31 1.04 10.16 0.16 -0.52 0.32 11.52 10.23 7.70 9.95 11.29 10.73 10.56
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
20 21 18 16 13 16 12 14 14 16 12 71
18 20 17 15 12 14 12 14 16 17 13 36
Operating Profit 1 1 1 1 1 1 0 -0 -1 -1 -1 35
OPM % 7% 6% 7% 7% 8% 7% 4% -2% -8% -8% -8% 50%
0 0 0 0 0 0 1 1 4 10 4 12
Interest 1 1 1 1 1 1 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 1
Profit before tax 1 0 0 0 0 1 0 1 2 8 3 46
Tax % 27% 14% 21% 23% 14% 9% 2% 0% 18% 5% 18% 26%
1 0 0 0 0 1 0 1 2 8 2 34
EPS in Rs 0.89 0.59 0.34 0.30 0.36 0.81 0.67 0.81 2.29 10.67 2.88 39.86
Dividend Payout % 0% 0% 0% 0% 83% 61% 74% 86% 392% 98% 87% 0%
Compounded Sales Growth
10 Years: 13%
5 Years: 42%
3 Years: 70%
TTM: 489%
Compounded Profit Growth
10 Years: 57%
5 Years: 140%
3 Years: 171%
TTM: 1484%
Stock Price CAGR
10 Years: 65%
5 Years: 66%
3 Years: 24%
1 Year: 170%
Return on Equity
10 Years: 18%
5 Years: 22%
3 Years: 26%
Last Year: 27%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 6 6 6 6 6 6 6 7 7 7 7 9
Reserves 4 4 4 5 5 9 9 13 15 16 17 219
6 6 7 7 8 6 6 4 2 3 2 1
7 7 7 6 5 5 5 4 4 5 4 21
Total Liabilities 23 24 25 24 24 26 27 28 29 32 30 250
3 3 3 3 3 2 2 2 2 3 3 7
CWIP 0 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 1 1 1 4 4 4 4 128
20 21 22 21 21 22 23 22 23 25 23 116
Total Assets 23 24 25 24 24 26 27 28 29 32 30 250

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-1 0 0 1 0 -1 0 1 3 8 2 28
-0 -0 -0 -0 0 -0 -0 -2 -0 -2 -0 -20
-0 0 -0 -1 -0 1 -0 1 -2 -6 -3 -4
Net Cash Flow -1 0 0 0 0 0 -0 0 1 0 -1 5

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 222 217 271 303 371 332 426 382 358 337 417 188
Inventory Days 136 106 128 121 190 108 176 116 88 81 127 144
Days Payable 204 175 204 190 237 115 156 108 95 108 88 65
Cash Conversion Cycle 155 148 196 234 323 326 447 390 351 311 456 267
Working Capital Days 219 222 282 331 428 410 549 494 447 431 588 225
ROCE % 9% 7% 6% 5% 6% 6% 4% 4% 9% 34% 11%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
38.35% 38.35% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 41.29%
1.47% 0.54% 1.23% 1.64% 1.64% 1.64% 2.11% 2.54% 3.06% 3.16% 3.38% 2.97%
0.09% 0.08% 0.08% 0.08% 0.08% 0.00% 0.00% 0.00% 0.00% 0.82% 1.18% 1.89%
60.09% 61.03% 60.26% 59.85% 59.85% 59.94% 59.47% 59.02% 58.50% 57.60% 56.99% 53.85%
No. of Shareholders 10,54116,25116,75616,46816,31615,41513,79813,13612,41610,51310,0889,753

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • May 2024
    Transcript
    Notes
    PPT
  • Feb 2024
    Transcript
    Notes
    PPT
  • Nov 2023
    Transcript
    Notes
    PPT
  • Aug 2023
    Transcript
    Notes
    PPT
  • May 2023
    Transcript
    Notes
    PPT
  • Feb 2023
    Transcript
    Notes
    PPT
  • Nov 2022
    Transcript
    Notes
    PPT
  • Sep 2022
    Transcript
    Notes
    PPT
  • Aug 2022
    Transcript
    Notes
    PPT
  • May 2022
    Transcript
    Notes
    PPT
  • Feb 2022
    Transcript
    Notes
    PPT
  • Nov 2021
    Transcript
    Notes
    PPT
  • Sep 2021
    Transcript
    Notes
    PPT
  • Jul 2021
    Transcript
    Notes
    PPT
  • Jun 2021
    Transcript
    Notes
    PPT
  • Feb 2021
    Transcript
    Notes
    PPT
  • Feb 2021
    Transcript
    Notes
    PPT
  • Nov 2020
    Transcript
    Notes
    PPT
  • Sep 2020
    Transcript
    Notes
    PPT
  • Jul 2020
    Transcript
    Notes
    PPT
  • Jun 2020
    Transcript
    Notes
    PPT
  • Feb 2020
    Transcript
    Notes
    PPT
  • Nov 2019
    Transcript
    Notes
    PPT
  • Jul 2019
    Transcript
    Notes
    PPT
  • May 2019
    Transcript
    Notes
    PPT
  • Jan 2019
    Transcript
    Notes
    PPT
  • Nov 2018
    Transcript
    Notes
    PPT
  • Aug 2018
    Transcript
    Notes
    PPT
  • May 2018
    Transcript
    Notes
    PPT
  • Feb 2018
    Transcript
    Notes
    PPT
  • Nov 2017
    Transcript
    Notes
    PPT
  • Jul 2017
    Transcript
    Notes
    PPT
  • Feb 2017
    Transcript
    Notes
    PPT